Clinical Trial Update: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC [Phase 4]

View source ↗

Summary

Phase 4 neoadjuvant trial of Aliya PEF Soft Tissue Ablation with systemic therapy in early-stage resectable non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Galvanize Therapeutics, Inc. | Conditions: NSCLC | Phase 4 | Status: TERMINATED